Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CFTR | P13569 | 11/20 | 0.50 |
| ▸ | SLC6A4 | P31645 | 5/20 | 0.45 |
| ▸ | SLC6A3 | Q01959 | 5/20 | 0.45 |
| ▸ | HDAC1 | Q13547 | 1/20 | 0.44 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.42 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL12345176 | 0.83 | CFTR (0.53) | CFTRSLC6A4SLC6A3HDAC1ALDH1A1 | |
| SCHEMBL699497 | 0.81 | CFTR (0.54) | CFTRSLC6A4SLC6A3HDAC1ALDH1A1 | |
| SCHEMBL15256569 | 0.80 | CFTR (0.50) | CFTRSLC6A4SLC6A3HDAC1ALDH1A1 | |
| SCHEMBL1466033 | 0.80 | CFTR (0.50) | CFTRSLC6A4SLC6A3HDAC1ALDH1A1 | |
| SCHEMBL3928369 | 0.80 | CFTR (0.50) | CFTRSLC6A4SLC6A3HDAC1ALDH1A1 | |
| SCHEMBL10203616 | 0.79 | CFTR (0.50) | CFTRSLC6A4SLC6A3HDAC1 | |
| SCHEMBL14458379 | 0.79 | CFTR (0.53) | CFTRSLC6A4SLC6A3HDAC1ALDH1A1 | |
| SCHEMBL13561358 | 0.79 | CFTR (0.59) | CFTRSLC6A4SLC6A3HDAC1 | |
| SCHEMBL19752991 | 0.77 | CFTR (0.52) | CFTRHDAC1 | |
| SCHEMBL15256631 | 0.77 | CFTR (0.48) | CFTRSLC6A4SLC6A3HDAC1ALDH1A1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8883766-B2 | Ion channel modulators and methods of use | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2014-11-11 | — | — | US | disclosed |
| US-20120208790-A1 | ION CHANNEL MODULATORS AND METHODS OF USE | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-08-16 | — | — | US | disclosed |
| US-8193194-B2 | Ion channel modulators and methods of use | VERTEX PHARMACEUTICALS INCORPORATED (US) | 2012-06-05 | — | — | US | disclosed |
| US-20080293737-A1 | ION CHANNEL MODULATORS AND METHODS OF USE | VERTEX PHARMACEUTICALS INCORPORATED | 2008-11-27 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20120208790-A1 | ION CHANNEL MODULATORS AND METHODS OF USE | CACNA1G, CACNA1C, CACNA1B | CFTR 249/4885SLC6A4 211/4885SLC6A3 265/4885 |
| US-20080293737-A1 | ION CHANNEL MODULATORS AND METHODS OF USE | CACNA1G, CACNA1C, CACNA1B | CFTR 249/4885SLC6A4 211/4885SLC6A3 265/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.